Relapsed hepatoblastoma confined to the lung is effectively treated with pulmonary metastasectomy

Shi, Yan; Geller, James I.; Irene, T.; Chavan, Rishikesh; Masand, Prakash; Towbin, Alexander J.; Chintagumpala, Murali; Nuchtern, Jed G.; Tiao, Greg; Thompson, Patrick A.; Vasudevan, Sanjeev A.

doi:10.1016/j.jpedsurg.2015.10.053

Cited by 34 publications

(46 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In our cohort, 4 of 5 of relapsed patients who remained in remission had complete resection of the recurrent lesions (liver = 3; lung = 1) with or without chemotherapy. The patient with pulmonary relapse remained disease‐free for 5.9 years after pulmonary metastectomy without further systemic treatment, in keeping with experience from the literature . Resection of residual pulmonary metastasis after neoadjuvant chemotherapy should also be attempted at the time of hepatic resection …”

Section: Discussionsupporting

confidence: 74%

“…The centralization of LT in one of the 5 pediatric oncology units meant that upfront, timely involvement of transplant physicians was not a routine and surgeons might be inclined to proceed with extended hepatectomy in potential transplant candidates. Among patients with hepatic or pulmonary relapse, resectability remains a major factor to impact long‐term survival . In our cohort, 4 of 5 of relapsed patients who remained in remission had complete resection of the recurrent lesions (liver = 3; lung = 1) with or without chemotherapy.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Treatment outcome and pattern of failure in hepatoblastoma treated with a consensus protocol in Hong Kong

Liu

Leung

et al. 2018

Pediatric Blood & Cancer

View full text Add to dashboard Cite

Background and aim:We reviewed the results and pattern of failure of the consensus HB/HCC 1996 treatment protocol for pediatric hepatoblastoma (HB) in Hong Kong. The role of SIOPEL and Children's Hepatic tumors International Collaboration (CHIC) risk stratification was evaluated. Methods:Patients enrolled on the protocol from 1996 to 2014 were included. PRETEXT staging, SIOPEL, and CHIC risk groups were retrospectively assigned.Results: Sixty patients were enrolled with median age at diagnosis of 1.1 years and median followup time of 6.8 years. Alpha-fetoprotein (AFP) was raised (>100 ng/mL) in 58 (97%) patients.Five (8%) had metastases at presentation and 7 (12%) experienced tumor rupture prior to or during treatment. Twenty-nine patients (48%) received a first-line cisplatin, 5-fluorouracil, and vincristine regimen only while 23 (38%) also had alternative chemotherapeutic agents. Hepatic resection could be performed in 48 (80%) patients. Three (5%) patients underwent upfront liver transplantation. Five-year event-free survival and overall survival rates were 69.2% ± 6.1% and 77.6% ± 5.5% respectively. Among the 16 patients with relapse/progression, 9 had intrahepatic failure only, 5 had distant failure only, and 2 had combined local and distant failure. Predictors of inferior outcome included advanced Evans staging, disease involving both lobes, rupture, low AFP, and suboptimal response to first-line chemotherapy. Assigned in 44 patients, PRETEXT staging, SIOPEL, and CHIC risk groups significantly predicted EFS and OS. Conclusions:Although the consensus HB/HCC 1996 protocol led to cure in three-quarters of pediatric HB patients, an upfront risk stratification system is required to identify and improve the outcome of high-risk patients. K E Y W O R D Shepatoblastoma, pediatric, pretreatment extent of disease, relapse, risk stratification

show abstract

Section: Discussionsupporting

confidence: 74%

Section: Discussionmentioning

confidence: 99%

Treatment outcome and pattern of failure in hepatoblastoma treated with a consensus protocol in Hong Kong

Liu

Leung

et al. 2018

Pediatric Blood & Cancer

View full text Add to dashboard Cite

show abstract

“…Отмечается два возрастных пика заболевае- мости -в 1-й и 16-18-й мес жизни. У детей старше 5 лет обычно имеет более агрессивное течение [17]. Клинические проявления.…”

Section: гепатобластомаunclassified

“…Наиболее часто гепатобластома метастазирует в легкие и кости. Регионарные лимфа-тические узлы печени поражаются чрезвычайно редко [17,18].…”

Section: гепатобластомаunclassified

See 1 more Smart Citation

Malignant Neoplasms in Children: Clinical Manifestations and Diagnosis

Rykov¹,

Севрюков²,

Vyalov³

2017

Vopr. sovr. pediatr.

View full text Add to dashboard Cite

Recent advances in surgical strategies and liver transplantation for hepatoblastoma

et al. 2022

View full text Add to dashboard Cite

Hepatoblastoma (HB) is the most common malignant liver tumor in children.Although the development of treatment strategies with advances in chemotherapy has greatly improved the prognosis of HB, surgical resection and liver transplantation still play a vital role in the treatment of HB. In recent years, technological innovations have led to the development of new surgical approaches for HB. In this review, we describe the latest research on the surgical management of HB, including new imaging technologies, minimally invasive approaches, and the application of associating liver partition portal vein ligation for staged hepatectomy. We also discuss the current role of liver transplantation, use of antesitum or ex-situ liver resection with auto-transplantation, and management of metastatic HB.

show abstract

Relapsed hepatoblastoma confined to the lung is effectively treated with pulmonary metastasectomy

Cited by 34 publications

References 27 publications

Treatment outcome and pattern of failure in hepatoblastoma treated with a consensus protocol in Hong Kong

Treatment outcome and pattern of failure in hepatoblastoma treated with a consensus protocol in Hong Kong

Malignant Neoplasms in Children: Clinical Manifestations and Diagnosis

Recent advances in surgical strategies and liver transplantation for hepatoblastoma

Contact Info

Product

Resources

About